Clinical review report: Ranolazine (Corzyna) (KYE Pharmaceuticals Inc.) : indication: stable angina pectoris, adults
The objective of this report is to perform a systematic review of the beneficial and harmful effects of ranolazine 500 mg and 1,000 mg ER tablets as an add-on therapy for the treatment of stable angina pectoris in adults who are inadequately controlled or intolerant to first-line antianginal therapi...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
August 2021, 2021
|
Edition: | Version: Final |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this report is to perform a systematic review of the beneficial and harmful effects of ranolazine 500 mg and 1,000 mg ER tablets as an add-on therapy for the treatment of stable angina pectoris in adults who are inadequately controlled or intolerant to first-line antianginal therapies |
---|---|
Physical Description: | 1 PDF file (74 pages) illustrations |